Wegovy Shot: The Injection, Formats and Dosing Basics

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The Wegovy shot: what it is

When people say "Wegovy shot," they mean the medication as it is actually sold: a once-weekly subcutaneous injection of semaglutide 2.4 mg. That is the only FDA-approved form of Wegovy as of April 2026. The search usually carries a follow-up question, though, about whether a pill exists and how the shot compares practically. This guide answers the format reality first, then the mechanics and cost.

Browse the full PlexusDx Education Hub library on GLP-1 therapies, weight protocols, and metabolic genetics.

Formats on the market in 2026

Wegovy itself comes only as the once-weekly subcutaneous injection; there is no oral Wegovy product. The oral form of semaglutide is Rybelsus, also from Novo Nordisk, and it is marketed for type 2 diabetes rather than chronic weight management. Separately, PlexusDx offers Semaglutide Injection and Semaglutide Oral as distinct protocols within its Weight Management Protocols, so the injection is not the only delivery route in the broader landscape.

Shot versus pill, mechanically

The injection route matters for a reason. Injectable GLP-1 receptor agonists deliver predictable bioavailability and dose once weekly for most products, or once daily in the case of liraglutide. Oral GLP-1 agonists have to survive gastric digestion first; Rybelsus uses the SNAC absorption enhancer and requires strict fasting administration to absorb. Head-to-head efficacy data between oral and injectable semaglutide in weight management is limited, and oral semaglutide is labeled for diabetes, not weight.

The dosing ladder for injectables

Semaglutide

Injectable semaglutide titrates per label from 0.25 mg weekly upward, with Ozempic reaching up to 2 mg and Wegovy up to 2.4 mg. The steps exist to ease tolerability, and the schedule is a provider's call.

Tirzepatide and oral

Injectable tirzepatide titrates from 2.5 mg weekly, with Mounjaro and Zepbound reaching up to 15 mg. Rybelsus, the oral option, starts at 3 mg daily and titrates to 7 or 14 mg. None of this substitutes for a prescriber's direction.

Cost and coverage by format

Injection and oral formats are priced separately, follow different insurance-coverage rules, and may qualify differently for manufacturer savings programs. PlexusDx Weight Management Protocols publish per-protocol pricing on each product page, so comparing the shot against an oral option means comparing the specifics rather than a single blended figure.

The biology upstream of the needle

Whether a molecule is delivered by injection or tablet, it acts on metabolic pathways that are yours alone. Understanding those pathways precedes the delivery-route decision.

Upstream of any GLP-1 decision, the PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, mapping variants such as FTO, GLP1R, MC4R, and TCF7L2 that shape your baseline appetite, satiety, and energy-balance biology. It never predicts how you will respond to a specific drug, and it is not a drug-response predictor; it simply gives you the metabolic backdrop to bring into a provider conversation. That is the test-before-you-invest sequence PlexusDx applies to every protocol: understand the biology first, then weigh the options with a clinician rather than guessing. To see the compounded protocols that pair with that context, explore the Weight Management Protocols collection, all delivered through licensed 503A compounding.

Practical realities of a weekly injection

Beyond bioavailability, the weekly cadence shapes daily life in ways worth considering. A once-weekly schedule means fewer administration moments to remember than a strict daily oral routine, which some people find easier to sustain. Others weigh injection tolerance heavily and prefer an oral option despite its timing rules. Neither preference is wrong; what matters is honest self-assessment about which routine you will actually follow, since adherence drives real-world results more than any format advantage on paper. A provider can help match the cadence to your life, your history, and the FDA-approved indication on your prescription, rather than defaulting to whichever format is most talked about. It is also worth remembering that the injection and any oral option are not the medication itself, only its delivery, so the effects trace back to the same pathway regardless of how the dose arrives.

Frequently Asked Questions

Is there an oral version of Wegovy?

Not as Wegovy. As of April 2026, Rybelsus is the only FDA-approved oral GLP-1 receptor agonist, and it is labeled for type 2 diabetes, not weight management. There is no FDA-approved oral tirzepatide. PlexusDx offers separate oral semaglutide and tirzepatide protocols through its Weight Management Protocols.

How does the shot compare with the pill?

The injection delivers predictable bioavailability with once-weekly dosing. Oral semaglutide uses an absorption enhancer and requires strict fasting administration per its label. Head-to-head weight-management efficacy data between the two formats is limited, and oral semaglutide is FDA-approved for type 2 diabetes, not chronic weight management.

Is the injection form right for me?

That depends on personal preference, injection tolerance, ability to follow timing requirements, insurance coverage, and goals of therapy. A prescribing provider weighs these against the FDA-approved indication, your history, concurrent medications, and side-effect considerations. PlexusDx provides both injection and oral options through its Weight Management Protocols.

Does the Precision Peptide Genetic Test predict how I'll respond to the shot?

No. It does not predict response to any compound or format. It analyzes pathway-level variants in genes such as FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology, the upstream context that applies whether a compound is delivered by injection or orally.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.